Cannabidiol - Echo Pharmaceuticals

Drug Profile

Cannabidiol - Echo Pharmaceuticals

Alternative Names: Arvisol; ECP 012A

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator Echo Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Schizophrenia
  • No development reported Epilepsy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Jul 2015 Phase-I clinical trials in Schizophrenia in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top